Steffen Desch

Steffen Desch

Auto-generated profile, based on publicly available information

Steffen Desch

Department of Internal Medicine/Cardiology, University of Leipzig Heart Center, Germany

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in American Journal of Hypertension
Verified
Journal Article
Open access
PDF file
SDSteffen Desch
Steffen Desch
JSJohanna Schmidt
Johanna Schmidt
DKDaniela Kobler
Daniela Kobler
MSMelanie Sonnabend
Melanie Sonnabend
IEIngo Eitel
Ingo Eitel
HTHolger Thiele
Holger Thiele
Background. Cocoa products such as dark chocolate and cocoa beverages may have blood pressure (BP)–lowering properties due to their high content of pla

1 June 2015 in Hypertension
Verified
Journal Article
Closed access
SDSteffen Desch
Steffen Desch
TOThomas Okon
Thomas Okon
DHDiana Heinemann
Diana Heinemann
KKKonrad Kulle
Konrad Kulle
KRKaroline Röhnert
Karoline Röhnert
PLPhilipp Lurz
Philipp Lurz
Few data are available with regard to the effectiveness of renal sympathetic denervation in patients with resistant hypertension yet only mildly elevated blood pressure (BP). Patients with resistant hypertension and slightly elevated BP (day-time systolic pressure, 135–149 and diastolic pressure, 90–94 mm Hg on 24-hour ambulatory measurement) were randomized in a 1:1 ratio to renal sympathetic denervation with the Symplicity Flex Catheter (Medtronic) or an invasive sham procedure. The primary efficacy end point was the change in 24-hour systolic BP at 6 months between groups in the intention to treat population. A total of 71 patients underwent randomization. Baseline day-time systolic BP was 144.4±4.8 mm Hg in patients assigned to denervation and 143.0±4.7 mm Hg in patients randomized to the sham procedure. The mean change in 24-hour systolic BP in the intention to treat cohort at 6 months was −7.0 mm Hg (95% confidence interval, −10.8 to −3.2) for patients undergoing denervation and −3.5 mm Hg (95% confidence interval, −6.7 to −0.2) in the sham group ( P =0.15). In the per protocol population, the change in 24-hour systolic BP at 6 months was −8.3 mm Hg (95% confidence interval, −11.7 to −5.0) for patients undergoing denervation and −3.5 mm Hg (95% confidence interval, −6.8 to −0.2) in the sham group ( P =0.042). In patients with mild resistant hypertension, renal sympathetic denervation failed to show a significant reduction in the primary end point of 24-hour systolic BP at 6 months between groups in the intention to treat analysis. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT01656096.

1 June 2010 in American Journal of Hypertension
Verified
Journal Article
Open access
PDF file
SDSteffen Desch
Steffen Desch
DKDaniela Kobler
Daniela Kobler
JSJohanna Schmidt
Johanna Schmidt
MSMelanie Sonnabend
Melanie Sonnabend
VAVolker Adams
Volker Adams
HTHolger Thiele
Holger Thiele
Background. Dark chocolate may have blood pressure-lowering properties. We conducted a prospective randomized open-label blinded end-point design trial

30 January 2011 in The International Journal of Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
SDSteffen Desch
Steffen Desch
HEHubertus Engelhardt
Hubertus Engelhardt
JMJosefine Meissner
Josefine Meissner
IEIngo Eitel
Ingo Eitel
MSMahdi Sareban
Mahdi Sareban
HTHolger Thiele
Holger Thiele

25 June 2014 in Trials
Verified
Journal Article
Open access
PDF file
SWSuzanne de Waha
Suzanne de Waha
IEIngo Eitel
Ingo Eitel
SDSteffen Desch
Steffen Desch
GFGeorg Fuernau
Georg Fuernau
PLPhilipp Lurz
Philipp Lurz
HTHolger Thiele
Holger Thiele
This study aimed to evaluate the incremental prognostic value of infarct size, microvascular obstruction (MO), myocardial salvage index (MSI), and left ventricular ejection fraction (LV-EFCMR) assessed by cardiac magnetic resonance imaging (CMR) in comparison to traditional outcome markers in patients with ST-elevation myocardial infarction (STEMI) reperfused by primary percutaneous intervention (PCI). STEMI patients reperfused by primary PCI (n = 278) within 12 hours after symptom onset underwent CMR three days after the index event (interquartile range [IQR] two to four). Infarct size and MO were measured 15 minutes after gadolinium injection. T2-weighted and contrast-enhanced CMR were used to calculate MSI. In addition, traditional outcome markers such as ST-segment resolution, pre- and post-PCI Thrombolysis In Myocardial Infarction (TIMI)-flow, maximum level of creatine kinase-MB, TIMI-risk score, and left ventricular ejection fraction assessed by echocardiography were determined in all patients. Clinical follow-up was conducted after 19 months (IQR 10 to 27). The primary endpoint was defined as a composite of death, myocardial reinfarction, and congestive heart failure (MACE). In multivariable Cox regression analysis, adjusting for all traditional outcome parameters significantly associated with the primary endpoint in univariable analysis, MSI was identified as an independent predictor for the occurrence of MACE (Hazard ratio 0.94, 95% CI 0.92 to 0.96, P <0.001). Further, C-statistics comparing a model including only traditional outcome markers to a model including CMR parameters on top of traditional outcome markers revealed an incremental prognostic value of CMR parameters (0.74 versus 0.94, P <0.001). CMR parameters such as infarct size, MO, MSI, and LV-EFCMR add incremental prognostic value above traditional outcome markers alone in acute reperfused STEMI. Clinicaltrials.gov NCT00463749 , Clinicaltrials.gov NCT00359918 .

14 September 2011 in Trials
Verified
Journal Article
Open access
PDF file
SDSteffen Desch
Steffen Desch
IEIngo Eitel
Ingo Eitel
SWSuzanne de Waha
Suzanne de Waha
GFGeorg Fuernau
Georg Fuernau
PLPhilipp Lurz
Philipp Lurz
HTHolger Thiele
Holger Thiele
Cardiac magnetic resonance (CMR) offers a variety of parameters potentially suited as surrogate endpoints in clinical trials of acute myocardial infarction such as infarct size, myocardial salvage, microvascular obstruction or left ventricular volumes and ejection fraction. The present article reviews each of these parameters with regard to the pathophysiological basis, practical aspects, validity, reliability and its relative value (strengths and limitations) as compared to competitive modalities. Randomized controlled trials of acute myocardial infarction which have used CMR parameters as a primary endpoint are presented.